Ovarian Cancer

Zejula Approved for HRD-Positive Advanced Ovarian Cancer

Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.
December 2019 Vol 5 No 6

In October 2019, the FDA approved a new indication for the PARP inhibitor Zejula (niraparib; from Tesaro) for the treatment of patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer, after receiving at least 3 chemotherapy regimens.

HRD is a type of genetic mutation defined by a deleterious or suspected deleterious BRCA mutation, or a genomic instability associated with disease progression more than 6 months after the tumor’s response to the last platinum-based chemotherapy.

Zejula has been previously approved by the FDA as maintenance treatment for patients these types of ovarian cancer but without HRD mutation.

Together with this new approval, the FDA also approved a new genetic test called Myriad myChoice CDx test, to identify patients with HRD mutation for Zejula therapy.

This new approval of Zejula was based on results of a clinical trial of patients with HRD-positive advanced ovarian cancer. Among the patients with HRD-positive status, 24% responded to treatment with Zejula, and the average duration of response was 8.3 months. Among patients with ovarian cancer and BRCA mutations, between 39% and 19% of patients responded to therapy with Zejula, depending on their response to platinum-based therapy.

Overall, 7% of patients had side effects with Zejula that required dose reduction or dose interruption, mostly because of infection, anemia, neutropenia, nausea, vomiting, fatigue, and abdominal pain.

Recommended For You
FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

Ovarian Cancer
Ovarian Cancer Patient Advocacy Organizations
There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.
Ovarian Cancer
Ovarian Cancer: Progress Occurs, but Far Too Slowly
By Annette Bennington McElhiney, PhD
As a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options.
Last modified: May 4, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.